SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Employees

8,311

Sector

Pharmaceuticals

Calendar

2025-04-24 - Q1 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-03	16.76 ¥	-1.47%	4,102,606
24-12-03	17.01 ¥	+0.06%	5,266,513
24-12-02	17.00 ¥	+0.89%	4,438,981
24-11-29	16.85 ¥	+0.36%	4,182,469
24-11-28	16.79 ¥	+0.06%	3,923,652

End-of-day quote Shanghai S.E., December 02, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart SHANDONG-BUCHANG-PHARMACE

More financial data

Annual profits - Rate of surprise

quality-estimates-chart SHANDONG-BUCHANG-PHARMACE

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2024-12-04			5-day change	1st Jan Change
16.76 ^CNY	-1.47%		+1.09%	-1.47%

06:30am	Buchang Pharmaceuticals Gets Drug Registration for Donepezil Hydrochloride Tablets	MT
06:16am	Buchang Pharmaceuticals Taps Beijing Excellence for Clinical Trial Registration	MT

Capitalization	18.13B 2.49B 2.37B 2.2B 1.97B 3.5B 211B 3.84B 27.41B 10.16B 86.43B 9.35B 9.14B 372B	P/E ratio 2022	-14x	P/E ratio 2023	59x
Enterprise value	20.37B 2.8B 2.66B 2.48B 2.21B 3.93B 237B 4.32B 30.81B 11.42B 97.15B 10.51B 10.27B 418B	EV / Sales 2022	1.58x	EV / Sales 2023	1.59x
Free-Float	41.28%	Yield 2022	4.57%	Yield 2023	0.74%

Buchang Pharmaceuticals Gets Drug Registration for Donepezil Hydrochloride Tablets	12:30am	MT
Buchang Pharmaceuticals Taps Beijing Excellence for Clinical Trial Registration	12:16am	MT
Shandong Buchang Pharmaceuticals Passes GMP Compliance for Meihekou, China Production Line	Dec. 02	MT
Buchang Pharmaceuticals to Invest 11 Million Yuan to Set Up Six Subsidiaries	Nov. 25	MT
Shandong Buchang Pharmaceuticals Plans Joint Investment in Establishing 95%-Owned Subsidiary	Nov. 22	MT
Buchang Pharmaceuticals Gets Drug Registration for Blood Sugar, Asthma Medications	Nov. 21	MT
Buchang Pharma Unit Gets Authorization for Vancomycin Hydrochloride Tablets	Nov. 14	MT
Buchang Pharmaceuticals Unit's 6% Equity Transferred to New Shareholders	Nov. 13	MT
Shandong Buchang Pharmaceuticals Unit Completes Registration Change for License	Nov. 13	MT
Shandong Buchang Pharmaceuticals Gets Clinical Trial Approval for Colon Cleansing Tablets	Nov. 13	MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.	Nov. 07	CI
Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback announced on December 14, 2023, has closed with 44,853,573 shares, representing 4.1% for CNY 712.38 million.	Nov. 05	CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	Oct. 28	CI

1 day	+0.06%
1 week	+2.59%
Current month	+0.95%
1 month	+1.43%
3 months	+15.79%
6 months	+11.54%

Shandong Buchang Pharmaceuticals Co., Ltd. Stock

Equities

603858

CNE100002FV6

Pharmaceuticals

Valuation: Shandong Buchang Pharmaceuticals Co., Ltd.

Chart: Shandong Buchang Pharmaceuticals Co., Ltd.

Latest news: Shandong Buchang Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shandong Buchang Pharmaceuticals Co., Ltd.

ETFs: Shandong Buchang Pharmaceuticals Co., Ltd.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Director	Title	Age	Since
Bao Cai Wang DFI	Director of Finance/CFO	61	2012-03-10
Chao Zhao PSD	President	57	2012-03-10
Xi Fang Wang CTO	Chief Tech/Sci/R&D Officer	65	2017-03-25

Manager	Title	Age	Since
Tao Zhao CHM	Chairman	58	2012-03-10
Chao Zhao BRD	Director/Board Member	57	2012-03-10
Yi Min Wang BRD	Director/Board Member	63	2017-03-25

	2022	2023
Net sales	14.95B 2.05B 1.95B 1.82B 1.62B 2.89B 174B 3.17B 22.61B 8.38B 71.29B 7.71B 7.54B 307B	13.25B 1.82B 1.73B 1.61B 1.44B 2.56B 154B 2.81B 20.03B 7.43B 63.15B 6.83B 6.68B 272B
Net income	-1.66B -227M -216M -202M -180M -320M -19.27B -351M -2.51B -929M -7.9B -855M -835M -34B	319M 43.78M 41.65M 38.8M 34.58M 61.59M 3.71B 67.62M 482M 179M 1.52B 165M 161M 6.55B
Net Debt	422M 57.9M 55.08M 51.31M 45.73M 81.45M 4.9B 89.42M 638M 237M 2.01B 218M 213M 8.66B	2.25B 308M 293M 273M 244M 434M 26.12B 476M 3.4B 1.26B 10.71B 1.16B 1.13B 46.11B

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.06%	+2.59%	-4.60%	-9.04%	2.49B
DONG-E-E-JIAO CO.,LTD.	+0.09%	+1.92%	+14.45%	+38.73%	5.14B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-1.15%	+1.30%	-30.91%	+3.49%	3.94B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.14%	+1.66%	-3.86%	+7.14%	3.01B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	+0.34%	-9.76%	+31.93%	2.95B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-0.95%	+4.27%	-8.19%	-4.82%	1.71B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+1.81%	+5.52%	+31.70%	+76.66%	1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.09%	+1.52%	-4.90%	-16.09%	1.65B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-0.17%	+3.69%	+63.02%	+109.40%	1.62B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	+1.33%	+5.76%	-36.90%	-33.71%	1.33B
Average	-0.09%	+1.32%	+1.01%	+20.37%	2.56B
Weighted average by Cap.	-0.20%	+0.94%	-0.53%	+20.97%